Free Trial

CG Oncology (CGON) Stock Price, News & Analysis

CG Oncology logo
$27.74 +0.80 (+2.97%)
Closing price 05/1/2025 04:00 PM Eastern
Extended Trading
$28.27 +0.53 (+1.91%)
As of 09:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CG Oncology Stock (NASDAQ:CGON)

Key Stats

Today's Range
$26.04
$27.88
50-Day Range
$15.59
$28.53
52-Week Range
$14.80
$46.99
Volume
916,716 shs
Average Volume
783,170 shs
Market Capitalization
$2.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.70
Consensus Rating
Buy

Company Overview

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

CG Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

CGON MarketRank™: 

CG Oncology scored higher than 42% of companies evaluated by MarketBeat, and ranked 833rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CG Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    CG Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CG Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CG Oncology is -19.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CG Oncology is -19.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about CG Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    19.74% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in CG Oncology has recently increased by 12.92%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CG Oncology does not currently pay a dividend.

  • Dividend Growth

    CG Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.74% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in CG Oncology has recently increased by 12.92%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CG Oncology has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 31 news articles for CG Oncology this week, compared to 4 articles on an average week.
  • Search Interest

    7 people have searched for CGON on MarketBeat in the last 30 days.
  • MarketBeat Follows

    4 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,760.00 in company stock.

  • Percentage Held by Institutions

    Only 26.56% of the stock of CG Oncology is held by institutions.

  • Read more about CG Oncology's insider trading history.
Receive CGON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter.

CGON Stock News Headlines

The next market Nvidia is positioned to dominate …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.
Why CG Oncology, Inc. (CGON) Surged on Monday
See More Headlines

CGON Stock Analysis - Frequently Asked Questions

CG Oncology's stock was trading at $28.68 at the beginning of 2025. Since then, CGON stock has decreased by 3.3% and is now trading at $27.74.
View the best growth stocks for 2025 here
.

CG Oncology, Inc. (NASDAQ:CGON) posted its quarterly earnings data on Tuesday, March, 25th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.11. The company earned $0.46 million during the quarter, compared to the consensus estimate of $0.11 million. CG Oncology had a negative trailing twelve-month return on equity of 18.97% and a negative net margin of 10,642.98%.

CG Oncology (CGON) raised $380 million in an initial public offering on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share.

CG Oncology's top institutional investors include TimesSquare Capital Management LLC (0.68%), Massachusetts Financial Services Co. MA (0.34%), Bank of New York Mellon Corp (0.19%) and Rhumbline Advisers (0.10%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche, Vijay Kasturi and Leonard E Post.
View institutional ownership trends
.

Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

Last Earnings
3/25/2025
Today
5/02/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGON
Previous Symbol
NASDAQ:CGON
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.56
High Stock Price Target
$75.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+114.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-48,610,000.00
Net Margins
-10,642.98%
Pretax Margin
-10,642.98%

Debt

Sales & Book Value

Annual Sales
$1.14 million
Price / Cash Flow
N/A
Book Value
($1.94) per share
Price / Book
-14.30

Miscellaneous

Free Float
N/A
Market Cap
$2.11 billion
Optionable
Optionable
Beta
1.24
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CGON) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners